Immunotherapy or antiangiogenic therapy plus chemotherapy as first-line treatment of patients with PD-L1(-) advanced non-squamous non-small cell lung cancer in a Chinese cohort.
Ruolan XiaYanying LiLing YangMeijuan HuangPublished in: Cancer medicine (2023)
Bevacizumab plus chemotherapy outperformed immunotherapy plus chemotherapy in terms of PFS.